Alzheimer’s in Focus as FDA Panel Endorses Lilly’s Donanemab
ZacksIf Eli Lilly’s (LLY) donanemab is approved by the FDA, it will become the second drug approved by the FDA to reduce the clinical decline associated with Alzheimer’s disease.
If Eli Lilly’s (LLY) donanemab is approved by the FDA, it will become the second drug approved by the FDA to reduce the clinical decline associated with Alzheimer’s disease.
